Regentis Biomaterials Ltd. (NYSE American: RGNT) Builds a Manufacturing and Intellectual Property Powerhouse for the Global Cartilage Repair Market
A new Japanese patent allowance follows a recent such US patent grant, strengthens protection around the organic solvent-free manufacturing process and ready-to-use liquid formulation behind GelrinC, extending the company's intellectual property footprint into one of the world's largest cartilage-repair markets. The process delivers a 5-fold increase in yield along with simplified production and commercial scalability, the manufacturing economics needed to make an off-the-shelf cartilage product commercially viable at scale. The milestone lands as Regentis advances European commercialization and passes the halfway mark in enrollment for its pivotal U.S. trial. Aging populations are pushing joint disease higher on the orthopedic agenda,…